HeartBeam to Present Results of ALIGN-ACS Study for Heart Attack Assessment at TCT 2026 on November 1, 2026
HeartBeam will present ALIGN-ACS pilot study results comparing its 3D ECG technology to a standard 12-lead ECG for acute coronary syndrome detection at TCT 2026 on November 1. The pilot enrolled 132 chest-pain patients across two sites in Belgrade, Serbia; results will inform the design of a U.S. pivotal study the company anticipates starting in Q1 2027.
Key figures
- Drug Name
- HeartBeam System (3D ECG technology)
- Phase Of Trial
- pilot study (ALIGN-ACS)
- Clinical sites
- two sites in Belgrade, Serbia
- Patients enrolled
- 132
- Pivotal study start
- first quarter 2027
- Acs diagnosed heart attack pct
- up to 80%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.